BCL-2-induced glioma cell invasiveness depends on furin-like proteases
Publication type: Journal Article
Publication date: 2004-10-27
scimago Q1
wos Q2
SJR: 1.499
CiteScore: 9.4
Impact factor: 4.0
ISSN: 00223042, 14714159
PubMed ID:
15584904
Biochemistry
Cellular and Molecular Neuroscience
Abstract
Migration and invasion are prerequisites for the neoplastic phenotype of malignant glioma. Ectopic expression of BCL-2 enhances migration and invasion of glioma cells and promotes their synthesis of transforming growth factor-β2 (TGF-β2). We here report that BCL-2-expressing cells show enhanced expression and activity of the proprotein convertase, furin, which processes metalloproteinases (MMP) and TGF-β. Consistent with a biological role for a BCL-2-dependent increase in furin-like protease (FLP) activity, BCL-2-expressing cells exhibit enhanced MMP activity. Both a pseudosubstrate furin inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethylketone (dec-RVKR-cmk), or alpha 1-anti-trypsin Portland (PDX), a recombinant furin-inhibitory protein, suppress constitutive and BCL-2-mediated MMP activity and invasion. This inhibition is not overcome by TGF-β or hepatocyte growth factor (HGF). A neutralizing TGF-β antibody attenuates, but not abrogates, the invasive properties conferred by exogenous expression of BCL-2, whereas the MMP inhibitor o-phenantroline (o-PA) abolishes the pro-invasive action of BCL-2. Exogenous HGF results in enhanced, and expression of dominant-negative ezrin in reduced, FLP activity, and dec-RVKR-cmk blunts the HGF-induced expression of mature TGF-β2. Consequently, HGF and BCL-2 family proteins use a furin-dependent pathway to promote invasion via TGF-β and MMP in human malignant glioma cells and the pro-invasive properties of TGF-β require furin- dependent MMP activity.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
International Journal of Molecular Sciences
2 publications, 5.26%
|
|
|
International Journal of Cancer
2 publications, 5.26%
|
|
|
Cancer Research
2 publications, 5.26%
|
|
|
Aging
1 publication, 2.63%
|
|
|
Oncotarget
1 publication, 2.63%
|
|
|
Molecular Medicine Reports
1 publication, 2.63%
|
|
|
International Journal of Oncology
1 publication, 2.63%
|
|
|
Clinical Medicine Insights: Oncology
1 publication, 2.63%
|
|
|
Frontiers in Immunology
1 publication, 2.63%
|
|
|
Frontiers in Cell and Developmental Biology
1 publication, 2.63%
|
|
|
Medical Oncology
1 publication, 2.63%
|
|
|
Investigational New Drugs
1 publication, 2.63%
|
|
|
PLoS ONE
1 publication, 2.63%
|
|
|
Neoplasia
1 publication, 2.63%
|
|
|
Journal of Immunological Methods
1 publication, 2.63%
|
|
|
Journal of Clinical Neuroscience
1 publication, 2.63%
|
|
|
Journal of Ethnopharmacology
1 publication, 2.63%
|
|
|
International Journal of Biological Macromolecules
1 publication, 2.63%
|
|
|
Trends in Pharmacological Sciences
1 publication, 2.63%
|
|
|
European Journal of Pharmacology
1 publication, 2.63%
|
|
|
Journal of Cellular Biochemistry
1 publication, 2.63%
|
|
|
Medicinal Research Reviews
1 publication, 2.63%
|
|
|
Journal of Magnetic Resonance Imaging
1 publication, 2.63%
|
|
|
Carcinogenesis
1 publication, 2.63%
|
|
|
APMIS
1 publication, 2.63%
|
|
|
Clinical Cancer Research
1 publication, 2.63%
|
|
|
Genes and Development
1 publication, 2.63%
|
|
|
Oncology Letters
1 publication, 2.63%
|
|
|
Oncology Reports
1 publication, 2.63%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
Elsevier
7 publications, 18.42%
|
|
|
Wiley
6 publications, 15.79%
|
|
|
Spandidos Publications
4 publications, 10.53%
|
|
|
Springer Nature
3 publications, 7.89%
|
|
|
American Association for Cancer Research (AACR)
3 publications, 7.89%
|
|
|
Impact Journals
2 publications, 5.26%
|
|
|
MDPI
2 publications, 5.26%
|
|
|
Frontiers Media S.A.
2 publications, 5.26%
|
|
|
Oxford University Press
2 publications, 5.26%
|
|
|
SAGE
1 publication, 2.63%
|
|
|
Public Library of Science (PLoS)
1 publication, 2.63%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 2.63%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 2.63%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
38
Total citations:
38
Citations from 2025:
2
(5.26%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Wick W. et al. BCL-2-induced glioma cell invasiveness depends on furin-like proteases // Journal of Neurochemistry. 2004. Vol. 91. No. 6. pp. 1275-1283.
GOST all authors (up to 50)
Copy
Wick W., Wild-Bode C., Frank B., Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases // Journal of Neurochemistry. 2004. Vol. 91. No. 6. pp. 1275-1283.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1111/j.1471-4159.2004.02806.x
UR - https://doi.org/10.1111/j.1471-4159.2004.02806.x
TI - BCL-2-induced glioma cell invasiveness depends on furin-like proteases
T2 - Journal of Neurochemistry
AU - Wick, Wolfgang
AU - Wild-Bode, Christine
AU - Frank, Brigitte
AU - Weller, M
PY - 2004
DA - 2004/10/27
PB - Wiley
SP - 1275-1283
IS - 6
VL - 91
PMID - 15584904
SN - 0022-3042
SN - 1471-4159
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2004_Wick,
author = {Wolfgang Wick and Christine Wild-Bode and Brigitte Frank and M Weller},
title = {BCL-2-induced glioma cell invasiveness depends on furin-like proteases},
journal = {Journal of Neurochemistry},
year = {2004},
volume = {91},
publisher = {Wiley},
month = {oct},
url = {https://doi.org/10.1111/j.1471-4159.2004.02806.x},
number = {6},
pages = {1275--1283},
doi = {10.1111/j.1471-4159.2004.02806.x}
}
Cite this
MLA
Copy
Wick, Wolfgang, et al. “BCL-2-induced glioma cell invasiveness depends on furin-like proteases.” Journal of Neurochemistry, vol. 91, no. 6, Oct. 2004, pp. 1275-1283. https://doi.org/10.1111/j.1471-4159.2004.02806.x.